Although current biomarkers such as PD-L1 expression have displayed inconsistent predictive value in ovarian cancer, future research should concentrate on identifying novel biomarkers, including immune-related genetic signatures, tumor mutational burden, and immune cell profiles. The gene discussed is CD274; the disease is ovarian carcinoma.